AbbVie Inc. $ABBV Stake Lowered by ProShare Advisors LLC

ProShare Advisors LLC decreased its position in AbbVie Inc. (NYSE:ABBV) by 12.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 942,552 shares of the company’s stock after selling 130,829 shares during the period. ProShare Advisors LLC’s holdings in AbbVie were worth $246,562,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Vise Technologies Inc. grew its stake in AbbVie by 21.7% in the third quarter. Vise Technologies Inc. now owns 143,948 shares of the company’s stock valued at $37,655,000 after purchasing an additional 25,704 shares in the last quarter. Investment Partners LTD. grew its holdings in AbbVie by 82.2% in the third quarter. Investment Partners LTD. now owns 10,925 shares of the company’s stock worth $2,858,000 after purchasing an additional 4,928 shares during the period. Global Assets Advisory LLC lifted its stake in AbbVie by 1.7% during the 3rd quarter. Global Assets Advisory LLC now owns 7,625 shares of the company’s stock valued at $2,008,000 after acquiring an additional 126 shares in the last quarter. Summit Global Investments lifted its stake in AbbVie by 45.1% in the third quarter. Summit Global Investments now owns 16,792 shares of the company’s stock valued at $4,393,000 after purchasing an additional 5,220 shares during the last quarter. Finally, Coyle Financial Counsel LLC boosted its stake in AbbVie by 3.1% in the 3rd quarter. Coyle Financial Counsel LLC now owns 8,020 shares of the company’s stock worth $2,098,000 after purchasing an additional 240 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on ABBV shares. Rothschild & Co Redburn upped their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Citigroup increased their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Cantor Fitzgerald raised their target price on shares of AbbVie from $285.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. Finally, Scotiabank lifted their price target on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $279.86.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Price Performance

ABBV stock opened at $294.80 on Friday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $298.74. The firm has a fifty day moving average price of $269.35 and a two-hundred day moving average price of $237.23. The firm has a market cap of $520.85 billion, a price-to-earnings ratio of 50.74, a PEG ratio of 1.35 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.86 earnings per share. As a group, analysts expect that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.